Heart Failure & Transplant
Four-pillar GDMT, vericiguat, LVADs and DCD heart transplantation.
Heart failure care is being rebuilt around the four-pillar foundation (ARNI, beta-blocker, MRA, SGLT2i), with vericiguat (VICTOR), finerenone (FINEARTS-HF), and dapagliflozin in acute HF (DAPA ACT HF-TIMI 68) extending the toolkit across the LVEF spectrum. The track addresses HFpEF phenotyping, GLP-1 use in obesity-driven HFpEF (STEP-HFpEF, SUMMIT), iron repletion, and rapid-titration protocols. Advanced therapy sessions cover HeartMate 3 destination outcomes, Impella 5.5 bridging, donation after circulatory death (DCD) transplantation, and the expanding multi-organ heart-kidney population. Cardiomyopathy-targeted therapy includes mavacamten, aficamten, acoramidis, vutrisiran and patisiran.
- Four-pillar GDMT and rapid sequencing protocols
- Vericiguat (VICTOR) and finerenone (FINEARTS-HF) integration
- HFpEF phenotyping and GLP-1 agonists (STEP-HFpEF, SUMMIT)
- Acute HF: DAPA ACT HF-TIMI 68 and decongestion strategies
- Mechanical circulatory support: HeartMate 3, Impella 5.5
- DCD heart transplantation and donor pool expansion
- HCM and ATTR-CM: mavacamten, aficamten, acoramidis, vutrisiran